Please contact us for more information or to learn if you are eligible to participate.
To evaluate the effect of tildacerfont in reducing GC use in subjects with CAH.
Principal Investigator | Surya N. Mulukutla, MD |
Co-PI | Luis Cantu Jr. |
Sponsor | Spruce Biosciences |
Type of Trial | Interventional |